Format

Send to

Choose Destination
J Biotechnol. 2000 Sep 29;83(1-2):3-12.

Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections.

Author information

1
Chirurgische Universitätsklinik der Universität Freiburg, Chirurgische Forschung, Hugstetter Strasse 55, 79106, Freiburg, Germany. specht@ch11.ukl.uni-freiburg.de

Abstract

Three different variants of the recombinant hybrid outer membrane protein OprF (aa 190-342)-OprI (aa 21-83) could be obtained in high yield after expression in Escherichia coli. The hybrid protein was modified N terminally, either with a minimal histidine tag or with a homologous sequence of OprF. Both recombinant proteins were purified by nickel chelate affinity chromatography under native and denaturing conditions, and this produced three suitable candidates for a vaccination trial, protein His-F-I, which was purified in its native as well as in its refolded form; and the native purified N terminally extended protein, ex-F-I. In mice, significantly higher antibody titers and survival rates after challenge with Pseudomonas aeruginosa were observed following immunization with protein His-F-I, purified under native conditions.

PMID:
11000453
DOI:
10.1016/s0168-1656(00)00311-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center